Overview

Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease

Status:
Terminated
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Patients who have relapsed or refractory large B-cell lymphoma are being asked to take part in this study. The purpose of this study is to find out what effects (good and bad) the drug thalidomide has on patients and the lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Emory University
Collaborator:
Celgene Corporation
Treatments:
Thalidomide